Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Assertio (ASRT) stocks in Canada

Learn how to easily invest in Assertio stocks.

Assertio Holdings Inc
NASDAQ: ASRT - USD
$2.29
- $0.05 ( - 2.14%)
DRUG MANUFACTURERS-SPECIALTY & GENERIC

Assertio is a drug manufacturers-specialty & generic business based in the US. Assertio stocks (ASRT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.62 – an increase of 13.59% over the previous week. Assertio employs 27 staff and has a trailing 12-month revenue of around $109.7 million.

How to buy shares in Assertio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ASRT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Assertio stock price (NASDAQ:ASRT)

Use our graph to track the performance of ASRT stocks over time.

Assertio shares at a glance

Information last updated 2022-01-25.
Latest market close$2.34
52-week range$0.85 - $5.80
50-day moving average $1.88
200-day moving average $1.52
Wall St. target price$4.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.78

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Assertio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Assertio price performance over time

Historical closes compared with the close of $2.34 from 2022-01-27

1 week (2022-01-21) 13.59%
1 month (2021-12-29) 21.24%
3 months (2021-10-29) 127.18%
6 months (2021-07-29) 78.63%
1 year (2021-01-29) 271.13%
2 years (2020-01-29) 110.81%
3 years (2019-01-29) 4.22
5 years (2017-01-27) 17.96

Is Assertio under- or over-valued?

Valuing Assertio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Assertio's EBITDA

Assertio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $34.1 million.

The EBITDA is a measure of a Assertio's overall financial performance and is widely used to measure a its profitability.

Assertio financials

Revenue TTM $109.7 million
Operating margin TTM 4.92%
Gross profit TTM $92.3 million
Return on assets TTM 1.07%
Return on equity TTM -35%
Profit margin -27.56%
Book value $2.17
Market capitalisation $95 million

TTM: trailing 12 months

Assertio share dividends

We're not expecting Assertio to pay a dividend over the next 12 months.

Have Assertio's shares ever split?

Assertio's shares were split on a 1:4 basis on 17 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assertio shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Assertio shares which in turn could have impacted Assertio's share price.

Assertio share price volatility

Over the last 12 months, Assertio's shares have ranged in value from as little as $0.85 up to $5.8. A popular way to gauge a stock's volatility is its "beta".

ASRT.US volatility(beta: 1.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio's is 1.664. This would suggest that Assertio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Assertio overview

Assertio Holdings, Inc. , a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site